Country: Јужноафричка Република
Језик: Енглески
Извор: South African Health Products Regulatory Authority (SAHPRA)
Schering
PROGYNOVA 1 mg AND 2 mg TABLETS SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): PROGYNOVA 1 mg AND 2 mg TABLETS For estrogen therapy of climacteric complaints in the postmenopause COMPOSITION Progynova tablets contain estradiol valerate (estra-1,3,5(10)-triene-3,17beta-diol 17-valerate) 1,0 mg and 2,0 mg respectively. PHARMACOLOGICAL CLASSIFICATION A. 21.8.1 Estrogens. PHARMACOLOGICAL ACTION Progynova contains estradiol valerate, an ester of the endogenous female estrogen, which following regular oral administration eliminates the characteristic estrogen deficiency symptoms in the postmenopause or after oophorectomy or radiological castration for non-carcinomatous diseases. INDICATIONS Climacteric complaints after the cessation of monthly bleeding or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness, bladder irritation, signs of muco-cutaneous involution. CONTRA-INDICATIONS Pregnancy; severe disturbances of liver function; jaundice or persistent itching during a previous pregnancy; Dubin- Johnson syndrome; Rotor syndrome; previous or existing liver tumours; existing or previous thromboembolic processes (eg stroke, myocardial infarction); sickle-cell anaemia; existing or suspected hormone-dependent tumours of the uterus or mammae; endometriosis; severe diabetes with vascular changes; congenital disturbances of lipometabolism; otosclerosis with deterioration in previous pregnancies. DOSAGE AND DIRECTIONS FOR USE Before starting Progynova a thorough general medical and gynaecological examination (including the breasts) should be carried out. Unless otherwise prescribed by the doctor, 1 tablet Progynova 2 mg is taken daily after a meal. The tablets ar Прочитајте комплетан документ